Renatus, Carbohyde sign MOU to co-develop novel cholesterol modulators for CNS disease applications.

Renatus was selected for the Scale-Up Challenge Lab program by Incheon Startup Park.

Renatus has been granted a key patent for novel cyclodextrins for the treatment of cholesterol-driven diseases by Korea Intellectual Property Office (KIPO).

Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).

Renatus was selected for the Startup-Focused University Program by Ministry of SMEs and Startups.

Renatus was selected for the Smart-X Bio program by Incheon Startup Park to support innovative bio startups.

Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).

Renatus, a pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases, today opened its official website to public.